A preparation method of sacubitril valsartan sodium tablets
By employing a refined operational structure involving stepwise mixing and sieving, combined with dynamic adjustment of the amount of added excipients, the problem of poor content uniformity and batch-to-batch consistency in the preparation of sacubitril/valsartan sodium tablets has been solved, achieving drug stability and formulation controllability, and is applicable to the field of tool battery technology.
Patent Information
- Application Number
- CN202611350816.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-02
- Publication Date
- 2026-11-13
AI Technical Summary
Existing technologies for preparing sacubitril/valsartan sodium tablets suffer from problems such as difficulty in ensuring content uniformity, poor batch-to-batch consistency, and poor process reproducibility. In particular, under conditions of high drug loading and easy hygroscopicity, this leads to poor drug stability and formulation quality.
The process employs a refined operational structure involving stepwise mixing and sieving. Sacubitril/valsartan sodium is first mixed with colloidal silica and microcrystalline cellulose and then sieved. Next, it is mixed with disintegrants, lubricants, and binders and sieved again. Finally, dry granulation is performed, and the amount of added excipients is dynamically adjusted according to the granulation yield to ensure uniform distribution of components.
It significantly improved the content uniformity and batch-to-batch consistency of sacubitril/valsartan sodium tablets, enhanced drug stability and formulation controllability, and ensured the quality reliability of industrial production.
Smart Images

Figure CN123078433A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of tool battery technology, and in particular to a method for preparing sacubitril / valsartan sodium tablets. Background Technology
[0002] Sacubitril / valsartan sodium is a novel salt complex cocrystal composed of sacubitril and valsartan, belonging to the angiotensin receptor-neprilysin inhibitor (ARNI) class. This drug works by inhibiting neprilysin via the active metabolite LBQ657 of sacubitril, thus promoting sodium excretion, diuresis, vasodilation, and cardiac protection. Simultaneously, valsartan blocks angiotensin II type 1 receptors (AT1), further dilating blood vessels and reducing cardiac workload. Sacubitril / valsartan sodium releases both sacubitril and valsartan simultaneously in vivo, resulting in a synergistic therapeutic effect significantly superior to a simple combination of the two drugs. Clinically, it is primarily used to treat chronic heart failure and hypertension.
[0003] Sacubitril / valsartan sodium is hygroscopic and readily deliquesces in environments with humidity levels exceeding 65%, leading to instability of the active ingredient and separation of the sacubitril and valsartan components. This, in turn, affects the preparation and storage of pharmaceutical formulations. Furthermore, this active pharmaceutical ingredient is sensitive to humid and hot conditions, and is prone to degradation impurities under high temperature and humidity, posing a challenge to the industrial production of formulations.
[0004] Currently, the main method for preparing sacubitril / valsartan sodium tablets is dry granulation. For example, existing technology (CN111358783A) discloses a preparation method in which sacubitril / valsartan sodium is mixed uniformly with all excipients in one step and then directly subjected to dry granulation. After granulation, some excipients are added, followed by tableting. The advantage of this method is its relatively simple process, but it has the following disadvantages:
[0005] (1) Content uniformity is difficult to guarantee: Sacubitril / valsartan sodium accounts for about 56.55% of the formulation, which is a high drug loading formulation. The active pharmaceutical ingredient itself has the tendency to electrostatic aggregation. After mixing all the materials at once, dry granulation is performed, which makes it difficult to ensure that the active pharmaceutical ingredient is fully dispersed in the mixture, which may result in unqualified content uniformity of the tablets.
[0006] (2) Poor batch-to-batch consistency: In the prior art, the added excipients are added according to a fixed prescription amount, without considering the impact of particle yield fluctuations during dry granulation. When the granulation yield deviates, the ratio of active ingredient to excipients in the final tablet will deviate from the theoretical design value, affecting the consistency between different batches of products.
[0007] (3) Poor process reproducibility: Existing technical literature points out that the dry granulation process has problems such as low yield, compressibility and poor reproducibility. It is difficult to achieve stable and controllable industrial production by directly adopting conventional dry granulation schemes.
[0008] To address the shortcomings of the existing technologies, it is necessary to develop a method for preparing sacubitril / valsartan sodium tablets that can improve content uniformity and batch-to-batch consistency. Summary of the Invention
[0009] To overcome the technical deficiencies of existing technologies, this invention provides a method for preparing sacubitril / valsartan sodium tablets, comprising the following steps:
[0010] Step 1: Sacubitril / valsartan sodium, colloidal silica, and microcrystalline cellulose are mixed to obtain a first mixture.
[0011] Step 2: The first mixture is sieved to obtain the second mixture;
[0012] Step 3: Mix the second mixture with crospovidone, talc, magnesium stearate and low-substituted hydroxypropyl cellulose, and then perform a second sieve to obtain the third mixture;
[0013] Step 4: Mix the third mixture a second time to obtain a fourth mixture;
[0014] Step 5: Dry granulate the fourth mixture to obtain granular material;
[0015] Step 6: Mix the granular material with the added excipients, compress the mixture into tablets, and obtain the sacubitril / valsartan sodium tablets.
[0016] Preferably, in step one, the first mixing is carried out using a column-type rotating hopper mixer with a mixing speed of 10 rpm and a mixing time of 3 min.
[0017] Preferably, in steps two and three, both the first sieve and the second sieve use sieves with a 1.0 mm aperture.
[0018] Preferably, in step four, the second mixing is carried out using a column-type rotating hopper mixer with a mixing speed of 10 rpm and a mixing time of 10 min.
[0019] Preferably, in step five, the parameters for dry granulation include: screw feed speed of 25 rpm to 30 rpm, pressure roller speed of 8 rpm to 12 rpm, roller pressure of 20 bar to 60 bar, roller gap of 0.5 mm to 1.5 mm, primary screen aperture of 2.0 mm, secondary screen aperture of 1.0 mm, primary granulation speed of 80 rpm to 110 rpm, and secondary granulation speed of 80 rpm to 110 rpm.
[0020] Preferably, in step six, the total mixing is carried out using a column-type rotating hopper mixer with a mixing speed of 10 rpm and a mixing time of 10 min.
[0021] Preferably, in step six, the added excipients include crospovidone, talc, and magnesium stearate.
[0022] In step six, before total mixing, there is also a step of calculating the amount of added auxiliary materials:
[0023] When the yield of the granular material obtained in step five is ≥95%, the added excipients are added according to the theoretical prescription amount;
[0024] When the yield of the granular material obtained in step five is less than 95%, the amount of the added auxiliary material shall be calculated according to the following formula:
[0025] The amount of each added auxiliary material = the theoretical formula amount of each added auxiliary material × (weight of qualified granules after granulation ÷ actual amount of raw and auxiliary materials added during granulation).
[0026] Preferably, the uncoated tablets obtained in step six are coated with a coating solution, and the weight gain of the coating is controlled to be 2.5% to 4.5%.
[0027] In the coating step, the inlet air temperature is 50℃~75℃, the inlet air volume is 700m³ / h~1700m³ / h, the main unit speed is 2rpm~15rpm, the spraying speed is 15rpm~30rpm, the atomization pressure is 0.1MPa~0.4MPa, the negative pressure is -30Pa~-70Pa, and the material temperature is 40℃~50℃.
[0028] The beneficial effects of this invention are:
[0029] 1. This invention breaks down the premixing stage into a refined operational structure of step-by-step mixing and sieving. Step one involves a first mixing of sacubitril / valsartan sodium with colloidal silica and microcrystalline cellulose. Utilizing the high specific surface area and strong adsorption properties of colloidal silica, the active pharmaceutical ingredient particles are fully dispersed and isolated, effectively preventing electrostatic aggregation and agglomeration. The first sieving granulates the dispersed premix into a second mixture with uniform particle size, laying the foundation for subsequent mixing. Step three involves adding a disintegrant (cross-linked povidone), a lubricant (talc, magnesium stearate), and a binder (low-substituted hydroxypropyl cellulose), followed by a second sieving and granulation. This ensures that materials with similar particle size distributions are fully and uniformly mixed in the second mixing step four. Compared to the conventional method of directly granulating all materials after a single mixing in the prior art, the step-by-step mixing, sieving, re-mixing, and re-sieving structure of this invention, through multiple alternating dispersion and granulation processes, results in more uniform contact and distribution among the components, significantly improving content uniformity.
[0030] 2. This invention introduces a dynamic adjustment mechanism for added auxiliary materials before final mixing. Based on the actual yield of particles after dry granulation, the amount of added auxiliary materials is dynamically adjusted. When the granulation yield is <95%, the amount of added auxiliary materials is adjusted according to the ratio of the actual particle weight to the theoretical input amount, ensuring that the proportions of each component in the final mixture are precisely constant. This solution overcomes the technical defects of existing technologies caused by batch-to-batch differences due to fluctuations in particle yield. Attached Figure Description
[0031] One or more embodiments are illustrated by way of example with reference numerals in the accompanying drawings. These illustrations do not constitute a limitation on the embodiments. Elements with the same reference numerals in the drawings are denoted as similar elements. Unless otherwise stated, the figures in the drawings are not to be limited by scale.
[0032] Figure 1 This is a schematic diagram of the preparation process of the present invention. Detailed Implementation
[0033] To make the objectives, technical solutions, and advantages of this invention clearer, the various embodiments of this invention will be described in detail below with reference to the accompanying drawings. However, those skilled in the art will understand that many technical details have been provided in the various embodiments of this invention to facilitate a better understanding of this application. However, the technical solutions claimed in the claims of this application can be implemented even without these technical details and with various variations and modifications based on the following embodiments.
[0034] like Figure 1 As shown, this embodiment provides a method for preparing sacubitril / valsartan sodium tablets, which mainly includes: a shell 1, a battery cell assembly 2, a battery management system (BMS) 3, a DC output module board 4, a main output contact interface 5, a USB-A output interface 6, a Type-C output interface 7, and a rubber dust cover 9.
[0035] Sacubitril / valsartan sodium tablets are available in 50mg strengths, with a batch size of 300,000 tablets. The formulation composition is as follows: Sacubitril / valsartan sodium is the active ingredient, 56.55mg per tablet, totaling 16.965kg for 300,000 tablets, representing 56.55% of the total formulation; microcrystalline cellulose PH102 is the filler, 17.45mg per tablet, totaling 5.235kg for 300,000 tablets, representing 17.45% of the total formulation; low-substituted hydroxypropyl cellulose LH-B1 is the binder, 12.50mg per tablet, totaling 3.750kg for 300,000 tablets, representing 12.50% of the total formulation; crospovidone XL is the disintegrant, with an internal portion of 5.00mg per tablet, totaling 1.50kg for 300,000 tablets, representing 5.00% of the total formulation; colloidal silica is the glidant, 0.50mg per tablet, totaling 0.15kg for 300,000 tablets, representing 0.50% of the total formulation. Talc 88-45 is a lubricant, with an internal dosage of 0.75 mg per tablet, totaling 0.225 kg for 300,000 tablets, representing 0.75% of the formulation; Magnesium stearate SH-YM-M is a lubricant, with an internal dosage of 1.50 mg per tablet, totaling 0.45 kg for 300,000 tablets, representing 1.50% of the formulation; Talc 88-45 is a lubricant, with an external dosage of 0.25 mg per tablet, totaling 0.075 kg for 300,000 tablets, representing 0.25% of the formulation; Magnesium stearate SH-YM-M is a lubricant, with an external dosage of 1.50 mg per tablet, totaling 0.45 kg for 300,000 tablets, representing 1.50% of the formulation; Crospovidone XL is a disintegrant, with an external dosage of 4.00 mg per tablet, totaling 1.20 kg for 300,000 tablets, representing 4.00% of the formulation. Each tablet contains 100.00 mg of internal and external excipients, and 300,000 tablets weigh a total of 30.00 kg, representing 100.00% of the prescription.
[0036] Coating formulation: A gastrointestinal film-coating premix is used as the coating material, with a dosage of 4.00 mg per tablet, totaling 1.20 kg for 300,000 tablets. The weight gain of the coating is controlled within the range of 4% ± 1%. Purified water is used as the coating solvent, with a dosage of 8.80 kg for 300,000 tablets. The coating solution is prepared at 1.5 times the prescribed dosage, meaning the actual dosage of the gastrointestinal film-coating premix is 1.80 kg, and the actual dosage of purified water is 13.20 kg. The purified water, used as the coating solvent, is completely removed during the coating drying process.
[0037] Unless otherwise specified, the following general operating parameters are used in the following examples and comparative examples.
[0038] Regarding environmental conditions, all processes—weighing, granulation, tableting, and coating—are carried out in a Class D cleanroom. The operating room temperature is between 18°C and 26°C. The relative humidity in the operating room is between 35% and 65%, and is controlled to not exceed 50% throughout the entire process. The tableting room is under relative negative pressure.
[0039] Regarding weighing requirements, electronic scales must be calibrated before their first use each day. A double-checking system must be implemented during weighing. The principle of weighing auxiliary materials before raw materials should be followed, and different materials should be handled in different weighing rooms to prevent cross-contamination. Weighed materials should be promptly labeled with the following information: product name, batch number, net weight, gross weight, weigher, checker, and date. Temperature and relative humidity should be recorded approximately every 60 minutes during the weighing process.
[0040] Regarding the cleaning requirements, after each process is completed, clean the equipment according to the standard operating procedures for cleaning and disinfecting cleanroom equipment, clean the containers and utensils according to the standard operating procedures for cleaning and disinfecting containers and utensils in Workshop 7, and clean the clean area according to the standard operating procedures for cleaning and disinfecting cleanrooms in Workshop 7. Batch production records and cleaning records must be filled out promptly.
[0041] Example 1: This example provides a method for preparing sacubitril / valsartan sodium tablets (50mg, batch of 300,000 tablets).
[0042] Weighing Procedure. According to the prescription, accurately weigh the following at the weighing center: 16.965 kg of sacubitril / valsartan sodium, 5.235 kg of microcrystalline cellulose PH102, 3.750 kg of low-substituted hydroxypropyl cellulose LH-B1, 1.50 kg of crospovidone XL (internal addition), 1.20 kg of crospovidone XL (external addition), 0.15 kg of colloidal silica, 0.225 kg of talc (internal addition), 0.075 kg of talc (external addition), 0.45 kg of magnesium stearate (internal addition), 0.45 kg of magnesium stearate (external addition), and 1.80 kg of film-coating premix (gastric-soluble type). Before weighing, check that the weighing room temperature is 18-26°C and the relative humidity is 35-65% and does not exceed 50%, confirming compliance with requirements. Operators should verify the material label information according to the batch production order, including material name, batch number or serial number, quantity, and properties. Following the order of excipients first, then raw materials, accurately weigh each excipient in the excipient weighing room and place it into two non-sterile material bags lined with sterile materials. Accurately weigh sacubitril / valsartan sodium in the raw material weighing room and place it into two non-sterile material bags lined with sterile materials. Immediately fill out the weighing material label with the following information: product name, specifications, batch number, material name, serial number, net weight, gross weight, weigher, checker, and weighing date. Transfer the entire batch of materials to the material return channel and notify the workshop to collect it. Materials requiring protection from light should be packaged in black plastic bags. Record the temperature and relative humidity approximately every 60 minutes during the weighing process. Clean the area after weighing.
[0043] Premixing and sieving steps. Premixing 1: Add 16.965 kg of sacubitril / valsartan sodium, 0.15 kg of colloidal silica, and 5.235 kg of microcrystalline cellulose (PH102) sequentially to the 200L hopper of an HZD-400 column-type rotary hopper mixer. Operate according to the standard operating procedures for the column-type rotary hopper mixer, setting the mixing speed to 10 rpm and the mixing time to 3 minutes. Start the equipment to mix. After mixing, place the material into a container lined with two non-sterile material bags, tie the bag openings tightly, and transfer to the next process. The mixed material is recorded as the first mixture.
[0044] Sieving Step 1: Add the first mixture to the LZ-300 dry granulator through the hopper of the STZ-300 fixed lifting transfer machine. Operate according to the standard operating procedures for the dry granulator, setting the screen mesh size to 1.0mm and the granulator speed to 28Hz. Start the equipment for sieving. If screen damage is found during sieving, stop the machine immediately, replace the screen, and re-sieve the material after the screen damage. After sieving, place the material in a hopper lined with two non-sterile material bags, and record this as the second mixture.
[0045] Sieving Step 2: Add 1.50 kg of crospovidone, 0.225 kg of talc, 0.45 kg of magnesium stearate, and 3.750 kg of low-substituted hydroxypropyl cellulose LH-B1 sequentially to the material bag containing the second mixture. Feed the mixture into an LZ-300 dry granulator via the hopper of an STZ-300 fixed-lift transfer machine. Set the screen aperture to 1.0 mm and the granulator speed to 28 Hz. Start the equipment for sieving. If screen damage is found during sieving, stop the machine immediately, replace the screen, and re-sieve the material after the screen damage. After sieving, place the material in a container lined with two non-sterile material bags, tie the bag openings tightly, weigh and record the weight, and transfer it to the next process. The sieved material is recorded as the third mixture.
[0046] Premix 2: Add the third mixture to the 200L hopper of the HZD-400 column-type rotary hopper mixer. Operate according to the standard operating procedures for the column-type rotary hopper mixer, setting the mixing speed to 10 rpm and the mixing time to 10 minutes. Start the equipment to mix. After mixing, place the material into a container lined with two non-sterile material bags, tie the bag openings tightly, and transfer it to the next process. The mixed material is recorded as the fourth mixture.
[0047] Dry granulation procedure. The fourth mixture is added to the LGS200 dry granulator using a vacuum feeding method. Operate according to the standard operating procedures for the dry granulator, presetting the following granulation parameters: screw feed speed 25 rpm, adjustable range 25 rpm to 30 rpm; pressure roller speed 9 rpm, adjustable range 8 rpm to 12 rpm; roller pressure 35 bar, adjustable range 20 bar to 60 bar; roller gap 0.5 mm to 1.5 mm; primary screen aperture 2.0 mm; secondary screen aperture 1.0 mm; primary granulation speed 80 rpm, adjustable range 80 rpm to 110 rpm; secondary granulation speed 80 rpm, adjustable range 80 rpm to 110 rpm. Start the equipment to begin granulation. Record the granulation parameters every 5 to 10 minutes during the granulation process. After granulation, place the material into a container lined with two non-sterile material bags, seal the bags tightly, and transfer to the next process.
[0048] The prepared granules are added to an S49-1000-2S series ternary vibrating screen, and 16-mesh and 80-mesh screens are installed to screen the dry granulation granules. Large granules that fail to pass through the 16-mesh screen are collected, weighed, and recorded as non-reusable material. Particles that pass through the 16-mesh screen and those that pass through the 80-mesh screen are collected separately, placed in two non-sterile material bags lined with rope, tied tightly, and then sealed in a stainless steel container with a sealing ring. The weight is recorded, a material label is filled out and attached, and the container is transferred to the next process.
[0049] In this embodiment, the total weight of materials input is 28.275 kg, including 16.965 kg of sacubitril / valsartan sodium, 0.15 kg of colloidal silica, 5.235 kg of microcrystalline cellulose, 1.50 kg of crospovidone, 0.225 kg of talc, 0.45 kg of magnesium stearate, and 3.75 kg of low-substituted hydroxypropyl cellulose. The weight of qualified granules after granulation is 27.285 kg. The granule yield is calculated according to the following formula: granule yield equals the weight of qualified granules after granulation divided by the total weight of materials input multiplied by 100%. In this embodiment, the granule yield is 27.285 divided by 28.275 multiplied by 100%, which equals 96.5%.
[0050] The final mixing step involves first calculating the amount of added excipients. In this example, the granule yield after dry granulation is 96.5%, which meets the condition of not less than 95%. Therefore, no calculation of added excipients is performed, and the materials are added according to the theoretical prescription, namely 1.20 kg of crosslinked polyvinyl chloride, 0.075 kg of talc, and 0.45 kg of magnesium stearate.
[0051] Then, the final mixing operation was performed. 27.285 kg of qualified granulated granules, 1.20 kg of cross-linked povidone, 0.075 kg of talc, and 0.45 kg of magnesium stearate were sequentially added to the 200L hopper of an HZD-400 column-type rotary hopper mixer. The mixing was performed according to the standard operating procedures for the column-type rotary hopper mixer, setting the mixing speed to 10 rpm and the mixing time to 10 minutes. The equipment was started for final mixing. After mixing, the material was placed in two non-sterile material bags lined with zip ties for sampling and testing. The bags were then sealed in a stainless steel container with a sealing ring, weighed, and labeled with the material name, batch number, specifications, weight, date, and operator's name. The material was then transferred to the intermediate storage room and affixed with the appropriate status label. In this example, the weight of the final mixed material was 29.01 kg, which is 27.285 kg of granules plus 1.725 kg of added additives.
[0052] Tableting steps. Before tableting, perform the following checks: confirm the cleaning certificate is valid; confirm production instructions and records are complete; confirm the tableting room temperature is 18-26℃, relative humidity is 35-65% and does not exceed 50%, and the tableting room is under relative negative pressure; confirm the equipment cleaning and disinfection are valid; confirm the electronic balance is within its calibration validity period and its zero point is calibrated; confirm the intermediate products have passed inspection and have an intermediate product release approval form.
[0053] The theoretical tablet weight is calculated based on the intermediate particle content. The theoretical tablet weight is calculated using the following formula: theoretical tablet weight equals 50mg of the specification divided by the intermediate particle content. In this example, the measured intermediate particle content is 0.985mg / mg, and the calculated theoretical tablet weight is 50 divided by 0.985, which equals 50.76mg. The tablet weight variation range is calculated as ±6.5%, with the lower limit being 50.76 multiplied by (1 minus 0.065) equaling 47.46mg, and the upper limit being 50.76 multiplied by (1 plus 0.065) equaling 54.06mg.
[0054] Operate the fully automatic dual-outlet high-speed tablet press according to the standard operating procedures, and perform a test press using a 6.5mm diameter circular die. Tableting parameters are set as follows: tableting speed 6.24 to 150,000 tablets / hour; internal standard tablet weight difference ±6.5%; hardness control 30N to 80N; friability not exceeding 1%, and no broken, cracked, or pulverized tablets should be detected. After passing the test press, formal tableting is performed. Connect the two tablet outlets to a tablet sieve machine and a metal detector. Operate the metal detector according to the corresponding standard operating procedures.
[0055] During the tableting process, approximately 20 tablets are taken every 15 minutes for tablet weight measurement and average tablet weight calculation. Ten tablets are taken to measure hardness and thickness, and parameters such as main compression, pre-compression, feeding speed, and filling thickness are recorded. The tablet weight measurement method is as follows: 20 tablets are placed in a container within an electronic balance and weighed. The average tablet weight is calculated by dividing by 20. Then, each tablet is removed from the container one by one using tweezers, and the weight of each tablet is recorded. The balance glass door must be closed after each step, and the reading should be taken only after the value stabilizes. Approximately 6.5g samples are taken from the left and right exits at the beginning, middle, and end of the tableting process for friability testing. Weight loss must not exceed 1%, and no broken, cracked, or pulverized tablets should be detected. If the tablet weight, hardness, or friability exceeds the specified range, the machine should be stopped immediately, and the excess material should be treated as unusable material. The compressed tablets were placed in two non-sterile material bags lined with tie ropes, then placed in a stainless steel container with a sealing ring, sealed, weighed, and labeled with the product name, batch number, specifications, quantity, person filling in the label, date, expiration date, serial number, and remarks. The tablets were then transferred to the intermediate storage room. In this example, the weight of the qualified compressed tablets was 28.72 kg.
[0056] Coating Procedure. First, prepare the coating solution. Prepare the coating solution according to a solid content of 12% (g / g). Prepare the coating solution at 1.5 times the prescribed amount. Accurately weigh 13.20 kg of purified water and place it in a mixing tank. Turn on the stirrer and adjust the speed to create a clear vortex in the purified water. Slowly add 1.80 kg of the stomach-soluble film coating premix to the purified water, while trying to prevent the powder from floating on the liquid surface. If necessary, increase the speed to maintain a suitable vortex. After all the coating premix has been added, stir for at least 45 minutes. Pass the mixture through a 100-mesh sieve. Add the sieved coating solution back to the mixing tank and continue stirring at low speed for later use.
[0057] Then preheat the uncoated sheets. Place the uncoated sheets to be coated in a BGB-75F high-efficiency coating machine and operate according to the high-efficiency coating machine operating procedures. Set the inlet air temperature to 50℃, adjustable range 50℃ to 65℃; main unit speed to 2 rpm, adjustable range 2 rpm to 15 rpm; inlet air volume to 1200 m³ / h, adjustable range 700 m³ / h to 1700 m³ / h; negative pressure to -50 Pa, adjustable range -30 Pa to -70 Pa. Turn on the main unit, exhaust, hot air, heating, and speed to preheat the material to above 40℃ and then dry for 15 minutes, maintaining the material temperature between 40 and 50℃ during the drying process. Weigh 100 dried uncoated sheets and record the weight, taking the average of two parallel measurements. Use the weight of the dried uncoated sheets as the starting point for the coating weight gain, denoted as m1.
[0058] Then, adjust the spray gun. Move the spray gun outside the coating machine and set the spray speed to 17 rpm, adjustable from 15 rpm to 30 rpm; the atomization pressure to 0.28 MPa, adjustable from 0.1 MPa to 0.4 MPa. Adjust according to the spraying situation. After the spray gun is spraying normally, move the spray gun back into the coating machine and adjust the spray gun to approximately 90° with the tablet bed surface.
[0059] Then, the coating liquid spraying is performed. Spraying begins after the uncoated flakes are preheated. The coating parameters are set as follows: inlet air temperature 55℃, adjustable range 50℃ to 75℃; inlet air volume 1200 m³ / h, adjustable range 700 m³ / h to 1700 m³ / h; negative pressure -50 Pa, adjustable range -30 Pa to -70 Pa; main unit speed 4 rpm, adjustable range 2 rpm to 15 rpm; spraying speed 17 rpm, adjustable range 15 rpm to 30 rpm; atomization pressure 0.28 MPa, adjustable range 0.1 MPa to 0.4 MPa. Spraying begins, and the material temperature is controlled between 40 and 50℃ during the spraying process. Coating weight gain is measured according to the coating progress. The sampling method is to weigh and record 100 coated flakes, taking two parallel samples and averaging the results, recorded as m2. The coating weight gain calculation formula is: coating weight gain equals (m2 minus m1) divided by m1 multiplied by 100%. Stop spraying when the coating weight increases to 3.5% to 4.0%.
[0060] After spraying, drying and cooling are performed. Drying parameters are set as follows: inlet air temperature 40℃; main unit speed 2 rpm, adjustable range 2 rpm to 15 rpm; inlet air volume 1200 m³ / h, adjustable range 700 m³ / h to 1700 m³ / h; negative pressure -50 Pa, adjustable range -30 Pa to -70 Pa. After drying for 10 minutes, heating is turned off for cooling. Once the material temperature has cooled to below 35℃, the machine is stopped and the material is discharged. 100 cooled coated sheets are weighed, and two parallel samples are taken as the average to calculate the coating weight gain. The acceptable range is 2.5% to 4.5%. In this embodiment, the measured coating weight gain is 3.8%, which is within the acceptable range.
[0061] The coated sheets were placed in a stainless steel drum lined with two non-sterile material bags, secured with cable ties, and sealed. The drum was weighed and labeled with the product name, batch number, specifications, quantity, person filling out the label, date, expiration date, serial number, and remarks. The drum was then transferred to the intermediate product storage room. In this example, the weight of the qualified coated sheets after coating was 29.79 kg. Assuming a 3.8% weight gain after coating, 28.72 kg multiplied by 1.038 equals 29.79 kg.
[0062] Aluminum-plastic packaging steps. Pre-production preparation: Confirm the site clearance certificate is valid; confirm production instructions and records are complete; confirm the packaging room temperature is 18-26℃ and relative humidity is 35-65%; confirm equipment cleaning and disinfection are valid; confirm the name, specifications, and quantity of the received pharmaceutical aluminum foil and PVC / PVC solid pharmaceutical composite sheets are correct; confirm the mold model is correct and install it; change the product batch number and expiration date mold according to the batch production instruction.
[0063] Operate according to the standard operating procedures of the fully servo high-speed roller blister packaging machine. Install the mold for sacubitril / valsartan sodium tablets and set the following parameters: upper heating plate temperature 120℃ to 160℃; lower heating plate temperature 120℃ to 160℃; heat sealing temperature 160℃ to 200℃; batch number temperature 80℃ to 100℃; punching speed 80 to 100 times / min. After successful debugging, proceed with aluminum-plastic packaging. The aluminum-plastic sheet should be flat, heat-sealed tightly, and the production batch number and expiration date should be correct and clear, with no missing tablets or damage.
[0064] During the aluminum-plastic packaging process, operators randomly inspect the quality of the aluminum-plastic sheets approximately every 60 minutes. Inspections include flatness, heat seal tightness, batch number and expiration date accuracy, clarity, and the presence of any missing or damaged sheets. Any non-compliance is addressed promptly. Samples are taken before, during, and after the aluminum-plastic packaging process, with the sample size representing all sheets cut by the packaging machine each time. Sealing tests are performed according to the standard operating procedures of the sealing tester, and the results are recorded to confirm good sealing. The qualified aluminum-plastic sheets are placed in a clean container, weighed, and the total number of qualified sheets is calculated. Material labels are affixed, and the sheets are then stored at the intermediate station.
[0065] Visual inspection steps. Pre-production preparation: Confirm that the previous cleaning certificate is valid at the production site; confirm that there is a batch production order and batch production record for this batch; confirm that there are no intermediate products or records unrelated to the current production at the visual inspection site; confirm that the tools and equipment used for production are complete and clean.
[0066] Perform the visual inspection operation according to the operating procedures. Inspect the aluminum composite panels to ensure they are flat, heat-sealed tightly, and that the production batch number, expiration date, and other details are correct and clearly visible, with no missing, broken, or damaged panels. Remove any non-compliant panels as unusable material. Neatly stack the visually inspected aluminum composite panels in a clean container, weigh them, calculate the quantity, affix material labels, and deliver them to the intermediate station for storage. After the visual inspection, the operator should tally the quantity of panels that passed and failed the inspection and promptly fill out the batch production record.
[0067] Example 2
[0068] The difference between this embodiment and Embodiment 1 is that the particle yield after dry granulation is different, and dynamic calculation of the added excipients is required.
[0069] In this embodiment, the total weight of materials input is 28.275 kg, the same as in Example 1. The weight of qualified granules after granulation is 26.085 kg. The granule yield is calculated according to the following formula: granule yield equals the weight of qualified granules after granulation divided by the total weight of materials input multiplied by 100%. In this embodiment, the granule yield is 26.085 divided by 28.275 multiplied by 100%, which equals 92.3%.
[0070] Since the granule yield is 92.3%, which is lower than 95%, the amount of added excipients needs to be recalculated according to the method of this invention. The amount of each added excipient is calculated according to the following formula: the amount of each added excipient is equal to the theoretical formula amount of each added excipient multiplied by (the weight of qualified granules after granulation divided by the actual amount of raw and auxiliary materials added during granulation).
[0071] The added amount of crospovidone is equal to 1.20 kg multiplied by (26.085 divided by 28.275) = 1.20 multiplied by 0.9225 = 1.107 kg. The added amount of talc is equal to 0.075 kg multiplied by (26.085 divided by 28.275) = 0.075 multiplied by 0.9225 = 0.069 kg. The added amount of magnesium stearate is equal to 0.45 kg multiplied by (26.085 divided by 28.275) = 0.45 multiplied by 0.9225 = 0.415 kg.
[0072] When mixing the total amount of additives, add them according to the converted amounts, namely 1.107 kg of crosslinked polyvinyl chloride, 0.069 kg of talc, and 0.415 kg of magnesium stearate. The remaining operating steps are the same as in Example 1.
[0073] In this embodiment, the total weight of the mixed materials is 26.085 plus 1.107 plus 0.069 plus 0.415, which equals 27.676 kg.
[0074] Example 3
[0075] The difference between this embodiment and Embodiment 1 is that the weight gain control target in the coating step is slightly different.
[0076] In this embodiment, the measured value of the preheated and dried uncoated sheet weight m1 and the coating process parameters are the same as in Example 1. However, during the coating weight gain test, the spraying was stopped when the coating weight gain reached between 2.5% and 3.5%. The final measured coating weight gain was 3.2%, which is within the acceptable range of 2.5% to 4.5%. The remaining operating steps are the same as in Example 1.
[0077] Comparative Example 1
[0078] This comparative example prepares sacubitril / valsartan sodium tablets according to existing technology, that is, all materials are mixed once and then granulated, and excipients are added according to a fixed prescription amount.
[0079] The prescription is the same as that in Example 1 of this invention.
[0080] The preparation method is as follows: Sacubitril / valsartan sodium and all internal excipients, including microcrystalline cellulose PH102, low-substituted hydroxypropyl cellulose LH-B1, crospovidone XL, talc, magnesium stearate, and colloidal silica, are all added at once to the 200L hopper of an HZD-400 column-type rotary hopper mixer. The mixing speed is set to 10 rpm and the mixing time is 10 min for one mixing. The mixed material is then directly subjected to dry granulation, with the granulation parameters being the same as in Example 1. After granulation, external excipients, including crospovidone XL, talc, and magnesium stearate, are added according to the theoretical prescription amount without dynamic calculation, and then added to the dry-granulated granules for total mixing, with the mixing parameters being the same as in Example 1. Tableting, coating, aluminum-plastic packaging, and visual inspection are all performed in the same manner as in Example 1.
[0081] The difference between Comparative Example 1 and Embodiment 1 of the present invention is that: the refined operation structure of stepwise mixing and sieving is not adopted, but all materials are mixed and granulated at once; the added excipients are added according to a fixed prescription amount, and no dynamic conversion is performed.
[0082] Comparative Example 2 differs from Example 2 in that, although the particle yield after dry granulation is also 92.3%, which is lower than 95%, the added excipients are still added at a fixed amount according to the theoretical prescription, without dynamic conversion. The remaining operating steps are the same as in Example 2.
[0083] Content uniformity was determined; the determination method was based on the content uniformity test method in General Chapter 0941 of Part IV of the 2020 edition of the Chinese Pharmacopoeia.
[0084] Samples: Example 1 (yield 96.5%, feed amount calculated based on theoretical amount after dynamic conversion), Example 2 (yield 92.3%, feed amount adjusted after dynamic conversion), Comparative Example 1 (yield 96.5%, feed amount calculated based on theoretical amount without conversion), Comparative Example 2 (yield 92.3%, feed amount calculated based on theoretical amount without conversion).
[0085] The measurement results are shown in the table below.
[0086] Sample number Particle yield (%) Additional auxiliary materials conversion method A+2.2S value Judgment Result Example 1 96.5 Conversion (based on theoretical quantity) 4.8 Compliant Example 2 92.3 Conversion (adjusted material input) 5.2 Compliant Comparative Example 1 96.5 No conversion (based on theoretical quantity) 11.6 Compliant Comparative Example 2 92.3 No conversion (based on theoretical quantity) 13.8 Compliant
[0087] Results analysis:
[0088] (1) Comparing Example 1 and Comparative Example 1, both had a particle yield of 96.5%, the difference being whether a step-mixing and sieving structure was used. The A+2.2S value of Example 1 was 4.8, which was significantly lower than that of Comparative Example 1 (11.6), indicating that the step-mixing-sieving structure significantly improved the uniformity of the content.
[0089] (2) Comparing Example 2 and Comparative Example 2, the particle yield of both was 92.3%. After dynamic conversion, the A+2.2S value of Example 2 was 5.2; while the A+2.2S value of Comparative Example 2 was 13.8 when the theoretical amount was used without conversion. This shows that dynamic conversion not only affects the accuracy of component ratios but also improves the uniformity of content.
[0090] (3) Comparing Comparative Example 1 (yield 96.5%) and Comparative Example 2 (yield 92.3%), when the particle yield deviated, the content uniformity further deteriorated without dynamic conversion (A+2.2S value increased from 11.6 to 13.8). However, after dynamic conversion, even if the particle yield decreased from 96.5% to 92.3%, the content uniformity remained good (A+2.2S value slightly increased from 4.8 to 5.2), indicating that dynamic conversion effectively compensated for the impact of process fluctuations.
[0091] Inter-batch consistency evaluation was conducted. The method involved taking three consecutive batches of each of Example 1, Example 2, Comparative Example 1, and Comparative Example 2, and measuring the RSD values for tablet weight and content between each batch. The test structure is shown in the table below.
[0092] sample Particle yield (%) Conversion method batch number Tablet weight variation RSD (%) Content RSD (%) Example 1 96.5 Conversion 20250501 0.72 1.15 20250502 0.68 1.08 20250503 0.75 1.21 Example 2 92.3 Conversion 20250504 0.81 1.32 20250505 0.79 1.28 20250506 0.85 1.35 Comparative Example 1 96.5 No discount 20250507 2.34 3.87 20250508 2.51 4.12 20250509 2.28 3.95 Comparative Example 2 92.3 No discount 20250510 3.12 5.23 20250511 3.35 5.48 20250512 3.08 5.16
[0093] Results analysis:
[0094] (1) Example 1 (yield 96.5%, calculated based on theoretical amount of feed) The weight difference RSD of three consecutive batches of tablets was ≤0.75%, and the content RSD was ≤1.21%, showing excellent batch-to-batch consistency.
[0095] (2) Example 2 (yield 92.3%, adjusted feed amount after conversion) The weight difference RSD of three consecutive batches of tablets was ≤0.85%, and the content RSD was ≤1.35%. Although the yield was lower than that of Example 1, it still maintained good batch consistency after dynamic conversion.
[0096] (3) Comparative Example 1 (yield 96.5%, without conversion) had a weight difference RSD of 2.28% to 2.51% and a content RSD of 3.87% to 4.12% for three consecutive batches, and the batch consistency was significantly worse than that of Example 1.
[0097] (4) In Comparative Example 2 (yield 92.3%, without conversion), the RSD of tablet weight variation across three consecutive batches was between 3.08% and 3.35%, and the RSD of content was between 5.16% and 5.48%, indicating the worst batch-to-batch consistency. Compared to Comparative Example 1, when the granule yield decreased from 96.5% to 92.3%, the non-conversion scheme led to a further increase in batch-to-batch fluctuations.
[0098] (5) Conclusion: This invention significantly improves batch-to-batch consistency through a stepwise mixing and sieving structure combined with a dynamic conversion mechanism for added excipients. Even with significant fluctuations in particle yield (92.3%), excellent batch-to-batch reproducibility is maintained. Those skilled in the art will understand that the above embodiments are specific examples of implementing this invention, and in practical applications, various changes in form and detail can be made without departing from the spirit and scope of this invention.
Claims
1. A method for preparing sacubitril / valsartan sodium tablets, characterized in that; Includes the following steps: Step 1: Sacubitril / valsartan sodium, colloidal silica, and microcrystalline cellulose are mixed to obtain a first mixture. Step 2: The first mixture is sieved to obtain the second mixture; Step 3: Mix the second mixture with crospovidone, talc, magnesium stearate and low-substituted hydroxypropyl cellulose, and then perform a second sieve to obtain the third mixture; Step 4: Mix the third mixture a second time to obtain a fourth mixture; Step 5: Dry granulate the fourth mixture to obtain granular material; Step 6: Mix the granular material with the added excipients, compress the mixture into tablets, and obtain the sacubitril / valsartan sodium tablets.
2. The method for preparing sacubitril / valsartan sodium tablets according to claim 1, characterized in that: In step one, the first mixing is carried out using a column-type rotating hopper mixer with a mixing speed of 10 rpm and a mixing time of 3 min.
3. The method for preparing sacubitril / valsartan sodium tablets according to claim 1, characterized in that: In steps two and three, both the first and second sieving processes use sieves with a 1.0 mm aperture.
4. The method for preparing sacubitril / valsartan sodium tablets according to claim 1, characterized in that: In step four, the second mixing is carried out using a column-type rotating hopper mixer with a mixing speed of 10 rpm and a mixing time of 10 min.
5. The method for preparing sacubitril / valsartan sodium tablets according to claim 1, characterized in that: In step five, the parameters for dry granulation include: screw feed speed of 25 rpm to 30 rpm, pressure roller speed of 8 rpm to 12 rpm, roller pressure of 20 bar to 60 bar, roller gap of 0.5 mm to 1.5 mm, primary screen aperture of 2.0 mm, secondary screen aperture of 1.0 mm, primary granulation speed of 80 rpm to 110 rpm, and secondary granulation speed of 80 rpm to 110 rpm.
6. The method for preparing sacubitril / valsartan sodium tablets according to claim 1, characterized in that: In step six, the total mixing is carried out using a column-type rotating hopper mixer with a mixing speed of 10 rpm and a mixing time of 10 min.
7. The method for preparing sacubitril / valsartan sodium tablets according to claim 1, characterized in that: In step six, the added excipients include crospovidone, talc, and magnesium stearate.
8. The method for preparing sacubitril / valsartan sodium tablets according to claim 1, characterized in that: In step six, before total mixing, there is also a step of calculating the amount of added auxiliary materials: When the yield of the granular material obtained in step five is ≥95%, the added excipients are added according to the theoretical prescription amount; When the yield of the granular material obtained in step five is less than 95%, the amount of the added auxiliary material shall be calculated according to the following formula: The amount of each added auxiliary material = the theoretical formula amount of each added auxiliary material × (weight of qualified granules after granulation ÷ actual amount of raw and auxiliary materials added during granulation).
9. The method for preparing sacubitril / valsartan sodium tablets according to claim 1, characterized in that: The uncoated tablets obtained in step six are coated with a coating solution, and the weight gain of the coating is controlled to be 2.5% to 4.5%. In the coating step, the inlet air temperature is 50℃~75℃, the inlet air volume is 700m³ / h~1700m³ / h, the main unit speed is 2rpm~15rpm, the spraying speed is 15rpm~30rpm, the atomization pressure is 0.1MPa~0.4MPa, the negative pressure is -30Pa~-70Pa, and the material temperature is 40℃~50℃.
Citation Information
Patent Citations
Pharmaceutical preparation of sacubitril valsartan sodium
CN111358783A
